Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

Abstract:

:Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicle) every 12 h for 30 days. Striatal dopamine (DA) receptors were analyzed by Scatchard plot using 3H-spiroperidol (3H-SP) as ligand. 3,4-Dihydroxyphenylacetic acid (DOPAC) and DA were measured by use of high pressure liquid chromatography. 6-OHDA lesions produced a supersensitivity in striatal DA receptors. Chronic L-Dopa or bromocriptine treatment reversed this supersensitivity. Neither lesion nor drug treatment alone or together produced a significant change in affinity (KD) for 3H-SP. Drug treatment alone also had no effect on Bmax. DA and DOPAC levels were reduced by greater than 98% in lesioned striata. Neither drug treatment affected DA or DOPAC levels as compared with controls. These results indicate that chronic administration of either bromocriptine or L-Dopa will reverse the DA receptor denervation supersensitivity in striatum seen following 6-OHDA lesion. This reversal may play a role in the clinical changes seen in Parkinson's disease patients following chronic use of these drugs.

journal_name

Clin Neuropharmacol

authors

Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

subject

Has Abstract

pub_date

1984-01-01 00:00:00

pages

247-57

issue

3

eissn

0362-5664

issn

1537-162X

journal_volume

7

pub_type

杂志文章
  • Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans.

    abstract::The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00005

    authors: Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

    更新日期:1993-04-01 00:00:00

  • The use of aminopyridines in neurological disorders.

    abstract::Aminopyridines are members of a family of monoamino and diamino derivatives of pyridine, and their principal mechanism of action is dose-dependent blockade of voltage-gated potassium channels, in particular, fast voltage-gated potassium channels. To date, only 2 main broad-spectrum potassium channel blockers, 4-aminop...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0b013e31825a68c5

    authors: Sedehizadeh S,Keogh M,Maddison P

    更新日期:2012-07-01 00:00:00

  • Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

    abstract:OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3181bbf45c

    authors: Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

    更新日期:2010-01-01 00:00:00

  • Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients.

    abstract::Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000188716.25211.58

    authors: Strous RD,Maayan R,Kotler M,Weizman A

    更新日期:2005-11-01 00:00:00

  • Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.

    abstract::We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Yoshida K,Higuchi H,Hishikawa Y

    更新日期:1998-01-01 00:00:00

  • New treatment strategies for bacterial meningitis.

    abstract::Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199310000-00001

    authors: Roos KL

    更新日期:1993-10-01 00:00:00

  • Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.

    abstract::Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182a124cb

    authors: Tomita T,Yasui-Furukori N,Kaneko S

    更新日期:2013-09-01 00:00:00

  • The relation between visual hallucinations and visual evoked potential in Parkinson disease.

    abstract:OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000157066.50948.65

    authors: Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

    更新日期:2005-03-01 00:00:00

  • Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.

    abstract:BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e318206785a

    authors: Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

    更新日期:2011-01-01 00:00:00

  • Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine.

    abstract::Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e3182a76fbb

    authors: Terhardt J,Lederbogen F,Feuerhack A,Hamann-Weber B,Gilles M,Schilling C,Lecei O,Deuschle M

    更新日期:2013-11-01 00:00:00

  • One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia.

    abstract::In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000404

    authors: Balcioglu YH,Gokcay H,Yesilkaya UH

    更新日期:2020-09-01 00:00:00

  • Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

    abstract::The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.wnf.0000168581.97083.9c

    authors: Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

    更新日期:2005-05-01 00:00:00

  • Central action of cinnarizine and flunarizine: a saccadic eye movement study.

    abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199410000-00003

    authors: Casucci G,Di Costanzo A,Riva R,Albani F,Bonavita V,Tedeschi G

    更新日期:1994-10-01 00:00:00

  • Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.

    abstract::Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000134853.36429.0e

    authors: Benito-León J

    更新日期:2004-07-01 00:00:00

  • Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

    abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000110

    authors: Ohta K,Osada T

    更新日期:2015-11-01 00:00:00

  • Place of dexfenfluramine in the management of obesity.

    abstract::The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Guy-Grand BJ

    更新日期:1988-01-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31823da9a8

    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • A review of the antiepileptic drug tiagabine.

    abstract::Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schachter SC

    更新日期:1999-11-01 00:00:00

  • Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons.

    abstract::Oxidant stress resulting from excess dopamine (DA) may contribute to the development and progression of Parkinson's disease (PD). Free radicals resulting from the enzymatic metabolism of DA are most often discussed in this regard. However, levodopa (L-DOPA) and DA can also undergo autooxidation, producing free radical...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619040-00010

    authors: Ling ZD,Pieri SC,Carvey PM

    更新日期:1996-08-01 00:00:00

  • First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.

    abstract::The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200305000-00011

    authors: Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

    更新日期:2003-05-01 00:00:00

  • Topiramate-Associated Movement Disorder: Case Series and Literature Review.

    abstract:BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000395

    authors: Rissardo JP,Caprara ALF

    更新日期:2020-07-01 00:00:00

  • Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

    abstract::Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000240956.49315.be

    authors: Fernandez HH,Chen JJ

    更新日期:2007-05-01 00:00:00

  • Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.

    abstract:OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0000000000000045

    authors: Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

    更新日期:2014-09-01 00:00:00

  • Calcium channel antagonists and the treatment of migraine.

    abstract::Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-198608000-00001

    authors: Greenberg DA

    更新日期:1986-01-01 00:00:00

  • Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole.

    abstract::Patients with schizophrenia often experience comorbid obsessive-compulsive syndromes (OCSs). Within these patients, a significant subgroup developed secondary OCS during treatment with antiserotonergic, atypical antipsychotic agents such as clozapine. Although cognitive behavioral therapy and antiobsessive antidepress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31819cc8e6

    authors: Englisch S,Esslinger C,Inta D,Weinbrenner A,Peus V,Gutschalk A,Schirmbeck F,Zink M

    更新日期:2009-07-01 00:00:00

  • Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms.

    abstract:OBJECTIVE:Although hormone replacement therapy (HRT) improves menopausal depressive symptoms, women unresponsive to HRT need an antidepressant drug as an effective adjunctive therapy. The aim of this study was to assess whether the herbal medicine Unkei-to has an impact on HRT-resistant menopausal depressive symptoms a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000138634.34498.05

    authors: Koike K,Ohno S,Takahashi N,Suzuki N,Nozaki N,Murakami K,Sugiura K,Yamada K,Inoue M

    更新日期:2004-07-01 00:00:00

  • Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I.

    abstract::The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal co...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199706000-00011

    authors: Toren P,Silbergeld A,Eldar S,Laor N,Wolmer L,Koren S,Weitz R,Inbar D,Reiss A,Eshet R,Weizman R

    更新日期:1997-06-01 00:00:00

  • Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects.

    abstract::The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198506000-00006

    authors: Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

    更新日期:1985-01-01 00:00:00

  • Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.

    abstract:OBJECTIVES:IPX066 is an oral, extended-release capsule formulation of carbidopa-levodopa (CD-LD) available in 4 strengths. The goals of this investigation were to assess the dose proportionality of IPX066 and to study the effects of a high-fat, high-calorie meal and of sprinkling the capsule contents on applesauce on t...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000126

    authors: Yao HM,Hsu A,Gupta S,Modi NB

    更新日期:2016-01-01 00:00:00

  • Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys.

    abstract::In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198602000-00010

    authors: Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

    更新日期:1986-01-01 00:00:00